You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

resectable NSCLC

Showing 1 - 25 of 4,682
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial (Dupilumab, Cemiplimab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Dupilumab
  • Cemiplimab
  • (no location specified)
Oct 12, 2023

NSCLC, Stage II-IIIA, Immunotherapy Trial in Shanghai (Serplulimab and Chemotherapy)

Recruiting
  • Non-small Cell Lung Cancer
  • +3 more
  • Serplulimab and Chemotherapy
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 27, 2023

NSCLC Trial in Hangzhou (sintilimab, pemetrexed, Carboplatin)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • sintilimab
  • +3 more
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
Jul 11, 2022

NSCLC Trial in Philadelphia (device, drug, other)

Not yet recruiting
  • NSCLC
  • Aliya Pulsed Electric Fields (PEF) ablation
  • +3 more
  • Philadelphia, Pennsylvania
    Temple University
Oct 24, 2022

NSCLC Trial in Burlington (cis-diamminedichloroplatinum)

Recruiting
  • Non-Small Cell Lung Cancer
  • Burlington, Vermont
    University of Vermont
May 20, 2022

NSCLC Trial (Durvalumab)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
Jun 22, 2023

Resectable NSCLC Trial (AK112, Carboplatin, Cisplatin)

Not yet recruiting
  • Resectable Non-small Cell Lung Cancer
  • (no location specified)
Feb 9, 2022

NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

Not yet recruiting
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • (no location specified)
Aug 27, 2023

NSCLC Trial in Xi'an (Furmonertinib+cisplating/pemetrexed)

Recruiting
  • Non-small Cell Lung Cancer
  • Xi'an, Shannxi, China
    Tangdu Hospital
Jun 20, 2022

Pembrolizumab Combined With Double Platinum Based Chemotherapy

Recruiting
  • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Feb 28, 2022

    NSCLC Trial in Beijing

    Recruiting
    • NSCLC
      • Beijing, China
        Yuyan Wang
      Oct 10, 2023

      Practical Usability of EGFR Mutation Detection in ctDNA From

      Recruiting
      • Lung Neoplasms
        • Seoul, Korea, Republic of
          Samsung Medical Center
        Aug 23, 2021

        NSCLC, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in New York (cemiplimab, Platinum Doublet)

        Recruiting
        • Non-small Cell Lung Cancer
        • +2 more
        • New York, New York
          Icahn School of Medicine at Mount Sinai
        Nov 24, 2021

        NSCLC Trial in Nanchang, Shanghai (KN046 plus Axitinib)

        Recruiting
        • NSCLC
        • KN046 plus Axitinib
        • Nanchang, Jiangxi, China
        • +1 more
        Aug 27, 2023

        NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)

        Not yet recruiting
        • Non-Small Cell Lung Cancer(NSCLC)
        • WX-0593 Tablets
        • Jinan, Shandong, China
          Shandong Cancer Hospital and Institute
        Mar 1, 2023

        High-Risk Resectable NSCLC Trial in Hangzhou (Nivolumab, Pembrolizumab)

        Recruiting
        • High-Risk Resectable NSCLC
        • Nivolumab, Pembrolizumab
        • Hangzhou, China
          The Second Affiliated Hospital Zhejiang University School of Med
        Oct 13, 2021

        Resectable Stage II-IIIB Driver Gene-negative Non-small Cell

        Not yet recruiting
        • NSCLC
          • Changsha, Hunan, China
            Hunan Cancer Hospital
          Aug 6, 2023

          NSCLC Trial in Philadelphia (Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days))

          Recruiting
          • Non-Small Cell Lung Cancer
          • Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
          • Philadelphia, Pennsylvania
            Fox Chase Cancer Center
          Jul 29, 2022

          Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

          Not yet recruiting
          • Non Squamous Non Small Cell Lung Cancer
          • EGFR Positive Non-small Cell Lung Cancer
          • Toripalimab plus Chemotherapy
          • (no location specified)
          Jul 28, 2023

          Squamous Cell NSCLC Trial in Hangzhou (Sintilimab, Carboplatin, Albumin-Bound Paclitaxel)

          Not yet recruiting
          • Squamous Cell Non-small Cell Lung Cancer
          • Sintilimab
          • +2 more
          • Hangzhou, Zhejiang, China
            Second Affiliated Hospital, School of Medicine, Zhejiang Univers
          Jun 19, 2022

          NSCLC Trial (JDQ443)

          Not yet recruiting
          • NSCLC
          • (no location specified)
          Feb 2, 2023

          NSCLC, Neoadjuvant Therapy Trial in Hangzhou (Serplulimab and neoadjuvant therapy, surgical resection of lung cancer)

          Recruiting
          • NSCLC
          • Neoadjuvant Therapy
          • Serplulimab and neoadjuvant therapy
          • surgical resection of lung cancer
          • Hangzhou, China
            2nd Affiliated Hospital, School of Medicine, Zhejiang University
          May 22, 2023

          NSCLC Trial in Seoul (Brigatinib)

          Not yet recruiting
          • Non-small Cell Lung Cancer
          • Seoul, Korea, Republic of
            Yonsei University Health System, Severance Hospital
          Apr 29, 2022

          NSCLC Trial in Canada, United States (Nivolumab, Carboplatin, Paclitaxel)

          Recruiting
          • Non-Small Cell Lung Cancer
          • Baltimore, Maryland
          • +4 more
          Jul 26, 2022

          Neoadjuvent, PD-1 Inhibitor, Lung Cancer Trial in Xi'an (neoadjuvant PD-1 inhibitor, anlotinib combined with chemo)

          Recruiting
          • Neoadjuvent
          • +4 more
          • neoadjuvant PD-1 inhibitor, anlotinib combined with chemotherapy
          • Xi'an, China
            Tangdu Hospital, the Air Force Military University
          May 26, 2022